Akiram Therapeutics, a Swedish biotech company specializing in molecular radiotherapy, has announced that new preclinical data on its lead candidate AKIR001 have been published in The Journal of Nuclear Medicine.
The results demonstrate selective tumor uptake, clear antitumor effects, and favorable tolerability in preclinical pancreatic cancer models, further strengthening the scientific foundation for AKIR001.
The article presents new preclinical data for AKIR001 in models of pancreatic cancer, one of the most aggressive cancer types with a significant unmet medical need. The findings demonstrate dose-dependent tumor growth inhibition and support the effective targeting of CD44v6 with molecular radiotherapy in CD44v6-positive tumors.
The lead candidate is currently undergoing Phase I clinical evaluation at Karolinska University Hospital.
The publication has also been highlighted by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) through its official channels. The recognition reflects the growing interest in targeted radiopharmaceuticals and CD44v6 as a therapeutic target in difficult-to-treat cancers.
“The study provides additional scientific support for AKIR001 and reinforces the preclinical foundation of our CD44v6-targeted strategy in molecular radiotherapy. The recognition by SNMMI also reflects the growing interest in targeted radiopharmaceuticals and CD44v6 as a therapeutic target,” says Marika Nestor, CEO of Akiram Therapeutics.
The ongoing Phase I clinical trial at Karolinska University Hospital enrolls patients with CD44v6-positive solid tumors who currently lack available treatment options. The trial evaluates safety, tolerability, and pharmacokinetics.
